Anti-Mullerian Hormone Actions to Control Primate Folliculogenesis
- Institution
- Oregon Health & Science University, OR
- Principal investigator
- Adam J Krieg
- Funding
- $565K
- Duration
- 2015–2026
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Anti-Müllerian hormone (AMH) plays a key role during ovarian follicular development. We have advanced our understanding of the dynamic expression, direct action, and physiological role of AMH during folliculogenesis in rhesus macaques since the initial award of the project. Data suggest that AMH is produced heterogeneously by developing follicles and exhibits stage-dependent regulatory effects by promoting preantral follicle growth and preventing antral follicle maturation. Stage-specific AMH modulation improves follicle growth and maturation in vitro to generate competent oocytes. Therefore, further research is warranted to elucidate the downstream molecular and cellular events regulated by AMH at the specific stages of follicular development, as well as the potential for modulation of AMH actions to improve ovarian function and female fertility. Our preliminary studies show that (a) AMH administration in vivo promotes preantral follicle growth, resulting in the increased number of antral follicles in the ovary; (b) primordial follicle activation and growth to the preantral stage is achieved by ovarian tissue culture after cryopreservation; and (c) preantral follicles are maintained in a state of physiological hypoxia. AMH has the potential to regulate cell cycle progression by limiting actions of hypoxia-inducible factor, and to control cellular energy production by inducing creatine biosynthesis and metabolism under hypoxia. Thus, studies will be performed to test the hypothesis that stage- specific modulation of AMH actions facilitates follicular development in vivo and in vitro, which in turn improves fertility outcomes. Aim 1 will evaluate the impact of AMH priming on ovarian response to gonadotropin stimulation during IVF (in vitro fertilization). AMH will be administered in vivo in macaques at advanced reproductive age or with poor response to controlled ovarian stimulation (COS). The COS protocol will then be performed to evaluate IVF efficacy. Aim 2 will examine the effect of AMH modulation on in vitro maturation of follicles from cryopreserved macaque and human ovarian tissue. Vitrified-warmed ovarian cortex will be cultured to induce primordial follicle activation and growth to the preantral stage. Preantral follicles will then be isolated and cultured with AMH modulation for oocyte maturation. Aim 3 will determine the molecular mechanisms whereby AMH regulates cell proliferation and energy production during follicular development. Macaque preantral follicles will be cultured at 5% O2 with AMH supplementation or knockdown. Factors regulating cell cycle progression and creatine biosynthesis/metabolic pathway components will be analyzed. The proposed studies will provide important insight into the mechanism of stage-dependent AMH actions in regulating follicular development and ovarian function using a nonhuman primate model that is an excellent surrogate for understanding reproductive processes in women. The findings will allow for developing protocols for optimizing IVF process, advancing options for female fertility preservation, and defining AMH-mediated regulation of cell cycle and energy metabolism during folliculogenesis.
LOADING MOONBASE SCORE
Questions for Oregon Health & Science University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Oregon Health & Science University60
mPFC Regulation of VTA Dopamine and GABA Neuronal Activity During Flexible Updating of Appetitive and Aversive Associations
Merridee Justice Lefner · $76K · 2024–2026
- NIH · Oregon Health & Science University59
Functional Mapping of the Suprachiasmatic Nucleus
Karen Jill Tonsfeldt · $224K · 2022–2028
- NIH · Oregon Health & Science University52
Molecular Aspects of Cytomegalovirus Latency
Meaghan H Hancock · $639K · 1984–2028